Adalimumab Clinical Trials

6 actively recruiting trials across 3 locations

No change since May 2026

Also known as: Humira, Simlandi

Pipeline

Phase 2: 1Phase 3: 2Phase 4: 1Phase 1/2: 1

Top Sponsors

University of Nebraska1
Universita di Verona1
Tom Appleton1
Swiss Dermatology Network for Targeted Therapies1
City of Hope Medical Center1

Indications

Arthritis5
Rheumatoid Arthritis2
New Onset1
Juvenile Psoriatic Arthritis1
Inflammatory Arthritis1

Other3 trials

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Phase 2

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Phase 4

Swiss Dermatology Network of Targeted Therapies (SDNTT)

Little Rock, Arkansas1 trial

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Arkansas Children's Hospital /ID# 258776

Phase 3

San Francisco, California1 trial

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

UCSF

Phase 1/2

Omaha, Nebraska1 trial

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

University of Nebraska Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.